AccessClosure Launches Mynx Cadence Vascular Closure Device

January 11, 2011—AccessClosure, Inc. (Mountain View, CA) announced the launch of the Mynx Cadence vascular closure device. The Mynx vascular closure device utilizes a conformable, water-soluble, polyethylene glycol sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but the healed artery. The first-generation Mynx received US Food and Drug Administration approval in May 2007.

According to the company, the Mynx Cadence offers all the benefits of the original Mynx, as well as a simpler design and improved ease-of-use for smoother device deployment. Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy: a definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling, a single marker on the advancer tube removes any guesswork around sealant compression, and a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to presoak during device preparation. 



"My initial experience with the Mynx Cadence has been very positive," commented Elias Kassab, MD. "The design changes inspire increased confidence in the device, but I don't feel that I've lost any of the tactile feedback I'm used to with the Mynx."